Suppr超能文献

[抗精神病药物所致高催乳素血症:病理生理学、临床特征及指导]

[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].

作者信息

Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C

机构信息

Service pharmacie, établissement public de santé mentale, 15 ter, rue Saint-Ouen, 14012 Caen cedex, France.

Service pharmacie, établissement public de santé mentale, 15 ter, rue Saint-Ouen, 14012 Caen cedex, France.

出版信息

Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5.

Abstract

BACKGROUND

Hyperprolactinemia is a frequent but neglected adverse effect observed in patients treated with antipsychotic-drugs. In this review, we summarize its physiopathogenetic mechanism, its clinical manifestations in men and women, and the way to manage it.

LITERATURE FINDINGS

Prolactin is a hormone secreted by lactotroph cells in the anterior pituitary. Its synthesis and release are under the control of peptides, steroids and neurotransmitters. The main inhibitory regulation is made by dopamine, which binds dopamine receptors D2 on the membrane of lactotroph cells. Antipsychotic-drugs block these receptors and thus remove the inhibitory effect of dopamine on prolactin secretion. All antipsychotic-drugs block D2 receptors and all can induce hyperprolactinemia. Nonetheless, it seems that the faster the antipsychotic-drug dissociates from D2 receptors, the lesser the increase of prolactin in the plasma. Another way to explain hyperprolactinemia is the ability of antipsychotic-drugs to cross the blood-brain barrier. The role of their metabolites should also be considered. For these reasons, one can distinguish prolactin-raising (conventional neuroleptics, amisulpride, risperidone) and prolactin-sparing (clozapine, aripiprazole, olanzapine) antipsychotics. An English study showed that 18% of men and 47% of women treated with antipsychotics for severe mental illness had a prolactin level above the normal range. Hyperprolactinemia is in fact more frequent in women than in men. Sometimes it is asymptomatic, but the higher the prolactin level is, the more patients have clinical manifestations. Some symptoms are due to the hypogonadism caused by prolactin, which disturbs hypothalamic-pituitary axis function, and others are due to direct effects on target tissues. Consequently, patients can suffer from sexual dysfunction, infertility, amenorrhea, gynecomastia or galactorrhoea. Data suggest that these symptoms are common, but patients don't mention them spontaneously and clinicians underestimate their prevalence. In the long-term, hypogonadism involves a premature bone loss in men and women. Klibanski and colleagues showed that this loss is significant only in women with hyperprolactinemia associated with amenorrhea. That suggests that prolactin is not directly responsible for this clinical feature. Nevertheless, prolactin seems to be involved in the development of breast cancer, but its role is unclear for prostate cancer.

DISCUSSION

Our review promotes a check-up before beginning a treatment with antipsychotic agents. First, a baseline prolactin level should be measured. It should also include the research on previous treatment with antipsychotic-drugs and the assessment of adverse effects suggestive of hyperprolactinemia. Questioning should finally look for any contra-indication to antipsychotics. Monitoring during antipsychotic treatment has been studied by a group of international experts in psychiatry, medicine, toxicology and pharmacy who made a critical review of clinical guidance on hyperprolactinemia. Experts notify that it is important to check whether patients have any sexual dysfunction, such as loss of libido or menstrual irregularity, and galactorrhoea. Prolactin level should also be controlled after three months of stable dose treatment, or if any clinical feature of hyperprolactinemia appears. If a patient prescribed antipsychotic-drugs has a confirmed prolactin level above the normal range, it is necessary to exclude other causes of hyperprolactinemia. If antipsychotics are really involved, the management should be adapted with the prolactin level and the patient him/herself. To summarize, clinicians can decrease the dose of the antipsychotic or switch to a prolactin-sparing drug. Oral contraceptives can be added whether to prevent pregnancy or to prevent bone loss and osteoporosis. Finally, experts recommend reserving dopamine agonists to treat antipsychotic-induced hyperprolactinemia in very exceptional circumstances as it can worsen the mental illness.

摘要

背景

高催乳素血症是抗精神病药物治疗患者中常见但被忽视的不良反应。在本综述中,我们总结了其生理病理发生机制、在男性和女性中的临床表现以及处理方法。

文献研究结果

催乳素是由垂体前叶的泌乳细胞分泌的一种激素。其合成和释放受肽类、类固醇和神经递质的控制。主要的抑制调节由多巴胺完成,多巴胺与泌乳细胞膜上的多巴胺D2受体结合。抗精神病药物阻断这些受体,从而消除多巴胺对催乳素分泌的抑制作用。所有抗精神病药物均阻断D2受体,均可诱发高催乳素血症。然而,似乎抗精神病药物与D2受体解离越快,血浆中催乳素的升高幅度越小。解释高催乳素血症的另一种方式是抗精神病药物穿过血脑屏障的能力。还应考虑其代谢产物的作用。基于这些原因,可区分出升高催乳素的(传统抗精神病药物、氨磺必利、利培酮)和不升高催乳素的(氯氮平、阿立哌唑、奥氮平)抗精神病药物。一项英国研究表明,因严重精神疾病接受抗精神病药物治疗的男性中有18%、女性中有47%的催乳素水平高于正常范围。事实上,高催乳素血症在女性中比在男性中更常见。有时它是无症状的,但催乳素水平越高,患者出现临床表现的可能性越大。一些症状是由于催乳素引起的性腺功能减退,干扰下丘脑 - 垂体轴功能,而其他症状则是由于对靶组织的直接影响。因此,患者可能会出现性功能障碍、不孕、闭经、男性乳房发育或溢乳。数据表明这些症状很常见,但患者不会主动提及,临床医生也低估了其患病率。从长远来看,性腺功能减退会导致男性和女性过早出现骨质流失。Klibanski及其同事表明,这种骨质流失仅在伴有闭经的高催乳素血症女性中显著。这表明催乳素并非直接导致这一临床特征。然而,催乳素似乎与乳腺癌的发生有关,但其在前列腺癌中的作用尚不清楚。

讨论

我们的综述提倡在开始抗精神病药物治疗前进行检查。首先,应测量基线催乳素水平。还应包括查询既往抗精神病药物治疗情况以及评估提示高催乳素血症的不良反应。最后,问诊应查找抗精神病药物的任何禁忌证。一组国际精神病学、医学、毒理学和药学专家对高催乳素血症的临床指南进行了批判性审查,研究了抗精神病药物治疗期间的监测情况。专家们指出,检查患者是否有任何性功能障碍,如性欲减退或月经不规律,以及溢乳情况很重要。在稳定剂量治疗三个月后,或出现高催乳素血症的任何临床特征时,也应检查催乳素水平。如果服用抗精神病药物的患者确诊催乳素水平高于正常范围,有必要排除高催乳素血症的其他原因。如果确实是抗精神病药物所致,应根据催乳素水平和患者自身情况进行处理。总之,临床医生可降低抗精神病药物的剂量或换用不升高催乳素的药物。可添加口服避孕药以预防怀孕或预防骨质流失和骨质疏松。最后,专家建议仅在非常特殊的情况下保留多巴胺激动剂来治疗抗精神病药物引起的高催乳素血症,因为它可能会使精神疾病恶化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验